Logo image
Back
Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non–small cell lung cancer
Journal article   Open access   Peer reviewed

Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non–small cell lung cancer

Howard West, Xiaohan Hu, Su Zhang, Yan Song, Diana Chirovsky, Chi Gao, Ari Lerner, Anya Jiang, James Signorovitch and Ayman Samkari
Journal of managed care & specialty pharmacy, v 29(7), pp 749-757
01 Jul 2023
DOI: https://doi.org/10.18553/jmcp.2023.29.7.749
PMID: 37404067
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.18553/jmcp.2023.29.7.749View
Published, Version of Record (VoR)Open Access (License Unspecified),  Open

Abstract

This study found that patients with non–small cell lung cancer (NSCLC) whose disease comes back are more likely to die sooner. They also use more health care resources and spend more on health care than those who remain tumor-free. The study also showed that patients whose disease comes back later are more likely to die later. These findings highlight the need to prevent or delay NSCLC recurrence to potentially reduce the negative consequences.

Metrics

28 Record Views
9 citations in Web of Science
9 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
Web of Science research areas
Health Care Sciences & Services
Pharmacology & Pharmacy
Logo image